<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373067">
  <stage>Registered</stage>
  <submitdate>1/06/2017</submitdate>
  <approvaldate>28/06/2017</approvaldate>
  <actrnumber>ACTRN12617000934347</actrnumber>
  <trial_identification>
    <studytitle>Transcranial Magnetic Stimulation in the diagnosis of Atypical Parkinsonism

</studytitle>
    <scientifictitle>Transcranial Magnetic Stimulation in the diagnosis of Atypical Parkinsonism

</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>PROGRESSIVE SUPRANUCLEAR PALSY</healthcondition>
    <healthcondition>MULTIPLE SYSTEM ATROPHY</healthcondition>
    <healthcondition>PARKINSON'S DISEASE</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Transcranial Magnetic Stimulation (TMS)
TMS will be performed on each participant  including measures of
intracortical inhibition and facilitation, resting motor thresholds and motor evoked potentials before and after theta burst stimulation. The TMS protocol is expected to take 2-3 hours. In addition each participant will undergo standardised cognitive tests. 
</interventions>
    <comparator>comparator is between disease entities and with normal control subjects, all participants will undergo the same examination and testing protocol. </comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Short interval cortical inhibition as measured by Transcranial Magnetic Stimulation  </outcome>
      <timepoint>single visit for each participant</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Excitability response to theta burst transcranial magnetic stimulation</outcome>
      <timepoint>single visit for all participants</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive changes as measured by Addenbrookes cognitive assessment(ACE-r)</outcome>
      <timepoint>single visit per participant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive assessment as measured by Frontal Assessment Battery (FAB)</outcome>
      <timepoint>single visit for each participant</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Four groups to be recruited:
1. 10 People with Progressive Supranuclear Palsy as defined by National Institute of Neurological Diseases and Stroke criteria
2. 15 People with "probable" or "possible" Multiple System Atrophy according to published consensus criteria (Golbe criteria)
3. 15 People with Parkinson's Disease according to Queens Square Brain Bank criteria
4. 20 normal controls over 40 years of age without symptoms of neurodegenerative brain disease or parkinsonism</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.People with epilepsy
2.People with intracranial metal which may increase the risk of seizures or injury due to Transcranial Magnetic Stimulation
3. People not able to complete clinical rating scales including cognitive assessment 
4. Patients deemed not capable of consenting to involvement in the study and for whom an appropriate
person responsible is not available to participate in the consenting process</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>between groups analysis of TMS measurements will be conducted, and correlation analysis between TMS recordings and cognitive assessment rating scales. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>7/07/2016</actualstartdate>
    <anticipatedenddate>29/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>29/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred - Prahran </hospital>
    <postcode>3004 - Prahran </postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Van Cleef Roet Centre for Nervous Diseases
Monash University
Level 4 Central Block
Commercial Road
Alfred Hospital
Melbourne
Victoria 3000
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Parkinson's Victoria</fundingname>
      <fundingaddress>587 Canterbury Rd Surrey Hills Victoria 3127</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Transcranial Magnetic Stimulation is capable of inducing action potentials in cortical neurones, and provides the capacity to measure cortical neuronal excitability and interneuronal function. Preliminary data in previous studies shows this may be a method for measuring neuronal function in Progressive Supranuclear Palsy, which may enable its use as a biomarker. The intention of this study
is to determine if these measurements are able to distinguish PSP from other parkinsonian syndromes with similar clinical features, 
ie. Multiple System Atrophy and Parkinson's Disease, and if these measurements correlate with markers of disease activity including cognitive changes. Results will also be compared with a group of healthy control participants to determine the reliability of these measurements. </summary>
    <trialwebsite />
    <publication>1. Conte, C. Belvisi, D. Bologna, M. Ottaviani, D. Fabbrini, G. Colosimo, C. Williams, DR. Berardelli, A. Abnormal cortical synaptic plasticity in primary motor area in progressive supranuclear palsy. Cerebral Cortex 2011:jun 15
2. Bologna, M. Bertram, K. Conte, A. Scott, K. Williams, DR. Berardelli, A. Reversal of long term potentiation-like plasticity in primary motor cortex in patients with Progressive Supranuclear Palsy. (abstract)</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>THE ALFRED HUMAN ETHICS COMMITTEE</ethicname>
      <ethicaddress>ALFRED HOSPITAL
COMMERCIAL ROAD
MELBOURNE
Victoria 3000</ethicaddress>
      <ethicapprovaldate>29/04/2016</ethicapprovaldate>
      <hrec>118/16</hrec>
      <ethicsubmitdate>18/02/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>David Williams</name>
      <address>Van Cleef Roet Centre for Neurosciences
Monash university
Level 4, central block
Alfred Hospital
Commercial Road
Melbourne 
Victoria 3000</address>
      <phone>+ 61 3 9076 2059</phone>
      <fax>+61 3 9076 2671</fax>
      <email>david.williams@monash.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kelly Bertram</name>
      <address>Van Cleef Roet Centre for Neurosciences
Monash university
Level 4, central block
Alfred Hospital
Commercial Road
Melbourne
Victoria 3000</address>
      <phone>+ 61 3 9076 2059</phone>
      <fax>+61 3 9076 2671</fax>
      <email>k.bertram@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kelly Bertram</name>
      <address>Van Cleef Roet Centre for Neurosciences
Monash University
Level 4, central block
Alfred Hospital
Commercial Road
Melbourne
Victoria 3000</address>
      <phone>+ 61 3 9076 2059</phone>
      <fax>+61 3 9076 2671</fax>
      <email>k.bertram@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kelly Bertram</name>
      <address>Van Cleef Roet Centre for Neurosciences
Level 4, central block
Alfred Hospital
Commercial Road
Melbourne</address>
      <phone>+ 61 3 9076 2059</phone>
      <fax>+61 3 9076 2671</fax>
      <email>k.bertram@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>